Longeveron Inc. (LGVN)
NASDAQ: LGVN · IEX Real-Time Price · USD
3.290
+0.040 (1.23%)
At close: Jul 19, 2024, 4:00 PM
3.350
+0.060 (1.82%)
Pre-market: Jul 22, 2024, 7:25 AM EDT
Company Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan.
The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.
It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome.
Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Longeveron Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Feb 12, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Mohamed Wa'el Ahmed Hashad M.B.A. |
Contact Details
Address: 1951 Nw 7th Avenue, Suite 520 Miami, Florida 33136 United States | |
| Phone | 305-302-7158 |
| Website | longeveron.com |
Stock Details
| Ticker Symbol | LGVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001721484 |
| CUSIP Number | 54303L104 |
| ISIN Number | US54303L1044 |
| Employer ID | 47-2174146 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mohamed Wa'el Ahmed Hashad | Chief Executive Officer and Director |
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer and Chairman |
| Lisa A. Locklear M.B.A. | Executive Vice President and Chief Financial Officer |
| Paul T. Lehr J.D. | International Executive Director, General Counsel and Secretary |
| Dr. Dan Gincel Ph.D. | Senior Vice President of Strategic Collaborations and Scientific Affairs |
| Dr. Nataliya Agafanova M.D. | Chief Medical Officer |
| Elly Ryu | Vice President and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 19, 2024 | 8-K | Current Report |
| Jul 19, 2024 | 424B5 | Filing |
| Jul 17, 2024 | 8-K | Current Report |
| Jul 10, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 10, 2024 | 424B3 | Prospectus |
| Jul 10, 2024 | 8-K | Current Report |
| Jul 9, 2024 | EFFECT | Notice of Effectiveness |
| Jul 3, 2024 | 8-K | Current Report |
| Jun 28, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 25, 2024 | D | Notice of Exempt Offering of Securities |